Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents.

[1]  D. Badesch,et al.  Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report , 2019, Chest.

[2]  Z. Jing,et al.  Risk stratification and medical therapy of pulmonary arterial hypertension , 2019, European Respiratory Journal.

[3]  Simon Gibbs,et al.  2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. , 2016, Revista espanola de cardiologia.

[4]  A. Praestgaard,et al.  Adverse Events in Connective Tissue Disease–Associated Pulmonary Arterial Hypertension , 2015, Arthritis & rheumatology.

[5]  H. Ghofrani,et al.  Selexipag for the Treatment of Pulmonary Arterial Hypertension. , 2014, The New England journal of medicine.

[6]  Simon Gibbs,et al.  [2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension]. , 2015, Kardiologia polska.

[7]  R. Benza,et al.  Unique Predictors of Mortality in Patients With Pulmonary Arterial Hypertension Associated With Systemic Sclerosis in the REVEAL Registry , 2014, Chest.

[8]  R. Benza,et al.  Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis. , 2013, Chest.

[9]  Mark D. Huffman,et al.  Survival in systemic sclerosis with pulmonary arterial hypertension has not improved in the modern era. , 2013, Chest.

[10]  Z. Jing,et al.  Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension: A Randomized, Controlled Trial , 2013, Circulation.

[11]  Z. Jing,et al.  Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. , 2013, Chest.

[12]  D. Badesch,et al.  Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. , 2012, Chest.

[13]  A. Torbicki,et al.  Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension , 2012, European Respiratory Journal.

[14]  P. Pellikka,et al.  Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension. , 2011, Chest.

[15]  S. Ghio,et al.  Prognostic relevance of the echocardiographic assessment of right ventricular function in patients with idiopathic pulmonary arterial hypertension. , 2010, International journal of cardiology.

[16]  H. Palevsky,et al.  Wide variation in clinicians' assessment of New York Heart Association/World Health Organization functional class in patients with pulmonary arterial hypertension. , 2009, Mayo Clinic proceedings.

[17]  J. Bronzwaer,et al.  Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. , 2007, European heart journal.

[18]  G. Koch,et al.  Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. , 2002, Journal of the American College of Cardiology.

[19]  B. Burnand,et al.  The RAND/UCLA Appropriateness Method User's Manual , 2001 .